 |
|
Calls for improved screening of colorectal cancer in Europe's aging population at ECCO 13
November 03, 2005Colorectal cancer is a significant public health problem for which differing treatment regimes hold different benefits in associated efficacy, safety and tolerability, according to study findings showcased at the 13th European Cancer Conference (ECCO).
Speaking at ECCO 13, leading expert in colorectal cancer epidemiology and prevention, Professor Peter Boyle from the International Agency for Research on Cancer (IARC), France, highlighted the important public health problem posed by the disease. In Europe in 2004, an estimated 197,200 men were diagnosed with colorectal cancer, representing 12.8% of new cancer cases. In the same year, colorectal cancer was diagnosed in approximately 179,200 women, representing 13% of new cancer cases and making it the second most common incident form of cancer in women.
Given that the majority of colorectal cancers occur in older people, and that the world's population as a whole is aging, this warrants further impetus to investigate prevention and treatment strategies among this subgroup of the population. Screening research, recommendations and implementation were highlighted by Professor Boyle as an obvious priority. In many European countries, only pilot programmes for colorectal screening are in place and mechanisms to ensure adequate coverage of the target groups need to be evaluated. However, some countries, such as Germany, have successfully implemented screening programmes. European Council Recommendations on Cancer Screening 2003 advise colorectal screening for men and women aged between 50 and 74. Professor Boyle concluded that Europe's goal should be to develop public health strategies to control the incidence of colorectal cancer in a rapidly aging European population.
With the situational perspective on colorectal cancer established, Nordic researchers presented their findings from a study evaluating different transatlantic treatment regimens for the metastatic form of the disease. Irinotecan combined with 5-fluorouracil (FU) and folinic acid (FA) is an established regimen for the treatment of metastatic colorectal cancer, however major uncertainties exist related to the mode of administration of FU. In the US, a weekly bolus schedule, the Saltz regimen, is used extensively, whereas in Europe, infused 5FU is preferred.
Irinotecan with the bolus FU/FA Nordic schedule (FLIRI) is a convenient treatment with efficacy and toxicity comparable to the 'infused' FOLFIRI regimen. In this study, irinotecan in combination with either the Nordic fortnightly 5FU/FA bolus schedule (FLIRI) or the fortnightly bolus/infused de Gramont schedule, known as FOLFIRI was administered to 557 previously untreated patients with metastatic colorectal cancer at 27 centres in the Nordic countries. The precise treatment schedule with FLIRI was irinotecan 180 mg/m2 on day 1, 5FU 500 mg/m2 bolus iv on day 1 and 2, plus FA 60 mg/m2 on days 1 and 2. In contrast, FOLFIRI consisted of irinotecan 180 mg/m2 on day 1, FA 200 mg/m2 on day 1 and 2, 5FU bolus 400 mg/m2 on day 1, 2 and infused 5FU 1 200 mg/m2 per 48 hour.
Results from the study were presented, with investigators highlighting that, in the entire patient population, toxicity did not differ between groups. The 60-day mortality was also similar between the two groups. Data on the primary endpoint of this study, which aims to assess any differences in progression-free survival between the two regimens, as well as response rates and time to progression will be available later in the year.
"Colorectal cancer imposes a significant burden of disease and all steps to improve and hone treatment regimens are an important undertaking," noted Dr Ake Berglund from Uppsala University, Sweden. "At ECCO we have seen evidence that irinotecan used with the bolus FLIRI schedule is a convenient treatment for metastatic colorectal cancer, with antitumour activity and toxicity comparable to the infused FOLFIRI regimen. Thus, patients can more easily be treated with a convenient bolus regimen without the need for a port and a pump."
About colorectal cancer
Colorectal cancer, also known as bowel cancer is the third most common cancer in men and the second most common in women.1,2There are approximately 377,000 cases of colorectal cancer across Europe each year and it is the cause of just under 204,000 deaths annually. 1
Colorectal cancer can occur anywhere in the colon or rectum. Cells lining the inside of the bowel are constantly renewing themselves and when this process goes wrong abnormal cells can arise. These cells form polyps which can eventually turn cancerous. Some of these polyps are non-cancerous but others can spread through the bowel layers and to other parts of the body, often the liver.
Symptoms experienced include: blood in faeces, changes in bowel habits, unexplained weight loss and a lump in the abdomen. Risk factors are associated with: age, (normally affects people over 50) history of chronic bowel inflammation, diet (high in red meat and fat and low in vegetables), lack of exercise, obesity, smoking and alcohol and family history.
There are three main treatments for colorectal cancer, surgery, radiotherapy and chemotherapy. If diagnosed early, surgery can be successful. Recently, innovations in chemotherapies such as irinotecan and experimental chemical agents are offering patients alternative treatments.
Federation of European Cancer Societies
With the situational perspective on colorectal cancer established, Nordic researchers presented their findings from a study evaluating different transatlantic treatment regimens for the metastatic form of the disease. Irinotecan combined with 5-fluorouracil (FU) and folinic acid (FA) is an established regimen for the treatment of metastatic colorectal cancer, however major uncertainties exist related to the mode of administration of FU. In the US, a weekly bolus schedule, the Saltz regimen, is used extensively, whereas in Europe, infused 5FU is preferred.
Irinotecan with the bolus FU/FA Nordic schedule (FLIRI) is a convenient treatment with efficacy and toxicity comparable to the 'infused' FOLFIRI regimen. In this study, irinotecan in combination with either the Nordic fortnightly 5FU/FA bolus schedule (FLIRI) or the fortnightly bolus/infused de Gramont schedule, known as FOLFIRI was administered to 557 previously untreated patients with metastatic colorectal cancer at 27 centres in the Nordic countries. The precise treatment schedule with FLIRI was irinotecan 180 mg/m2 on day 1, 5FU 500 mg/m2 bolus iv on day 1 and 2, plus FA 60 mg/m2 on days 1 and 2. In contrast, FOLFIRI consisted of irinotecan 180 mg/m2 on day 1, FA 200 mg/m2 on day 1 and 2, 5FU bolus 400 mg/m2 on day 1, 2 and infused 5FU 1 200 mg/m2 per 48 hour.
Results from the study were presented, with investigators highlighting that, in the entire patient population, toxicity did not differ between groups. The 60-day mortality was also similar between the two groups. Data on the primary endpoint of this study, which aims to assess any differences in progression-free survival between the two regimens, as well as response rates and time to progression will be available later in the year.
"Colorectal cancer imposes a significant burden of disease and all steps to improve and hone treatment regimens are an important undertaking," noted Dr Ake Berglund from Uppsala University, Sweden. "At ECCO we have seen evidence that irinotecan used with the bolus FLIRI schedule is a convenient treatment for metastatic colorectal cancer, with antitumour activity and toxicity comparable to the infused FOLFIRI regimen. Thus, patients can more easily be treated with a convenient bolus regimen without the need for a port and a pump."
About colorectal cancer
Colorectal cancer, also known as bowel cancer is the third most common cancer in men and the second most common in women.1,2There are approximately 377,000 cases of colorectal cancer across Europe each year and it is the cause of just under 204,000 deaths annually. 1
Colorectal cancer can occur anywhere in the colon or rectum. Cells lining the inside of the bowel are constantly renewing themselves and when this process goes wrong abnormal cells can arise. These cells form polyps which can eventually turn cancerous. Some of these polyps are non-cancerous but others can spread through the bowel layers and to other parts of the body, often the liver.
Symptoms experienced include: blood in faeces, changes in bowel habits, unexplained weight loss and a lump in the abdomen. Risk factors are associated with: age, (normally affects people over 50) history of chronic bowel inflammation, diet (high in red meat and fat and low in vegetables), lack of exercise, obesity, smoking and alcohol and family history.
There are three main treatments for colorectal cancer, surgery, radiotherapy and chemotherapy. If diagnosed early, surgery can be successful. Recently, innovations in chemotherapies such as irinotecan and experimental chemical agents are offering patients alternative treatments.
Federation of European Cancer Societies
Colorectal Cancer News and Current Colorectal Cancer Events RSSStudy confirms colorectal cancer screening should start at age 50
Colorectal adenomas, the precursor polyps in virtually all colorectal cancers, occur infrequently in younger adults, but the rate sharply increases after age 50.
PET scans lead to treatment changes in majority of colorectal cancer patients
In the largest multi-institutional study to date examining the impact of positron emission tomography (PET) in changing disease management of individuals with suspected recurrent colorectal cancer, researchers found that treatment plans were changed for more than half of patients.
Obesity raises risks of serious digestive health concerns
The prevalence of obesity and overweight in the United States coupled by the increased risk of gastrointestinal diseases related to obesity raises serious implications for the health of Americans.
Bowel cancer indicator should lead to better treatment
STEM cell scientists have developed a more accurate way of identifying aggressive forms of bowel cancer, which should eventually lead to better treatment and survival rates.
Stem cell indicator for bowel cancer should lead to better survival rates
Stem cell scientists have developed a more accurate way of identifying aggressive forms of bowel cancer, which should eventually lead to better treatment and survival rates. Bowel cancer is the third most common cancer in the UK.
Scientists discover major genetic cause of colorectal cancer
About one-third of colorectal cancers are inherited, but the genetic cause of most of these cancers is unknown. The genes linked to colorectal cancer account for less than 5 percent of all cases.
Perceived discrimination affects screening rates
Minority men and women who perceived discrimination from their health care providers were less likely to be screened for colorectal or breast cancer, according to a report in the August issue of Cancer Epidemiology, Biomarkers and Prevention, a journal of the American Association for Cancer Research.
First worldwide analysis of cancer survival finds wide variation between countries
Cancer survival varies widely between countries according to a worldwide study published online today in Lancet Oncology.* More than 100 investigators contributed to the study.
'Smothered' genes combine with mutations to yield poor outcome in cancer patients
Johns Hopkins Kimmel Cancer Center researchers have identified a set of genes in breast and colon cancers with a deadly combination of traditional mutations and "smothered" gene activity that may result in poor outcomes for patients.
Protein thought to promote cancer instead functions as a tumor suppressor, researchers report
A protein previously thought to promote colorectal cancer instead suppresses the growth of human cancer cells in culture, researchers at UT Southwestern Medical Center have found.
More Colorectal Cancer News Articles
 | American Cancer Society's Complete Guide to Colorectal Caner by American Cancer Society Don't die of embarrassment--get informed about colorectal cancer Although colorectal cancer is the third most common cancer found in men and women, you may be unaware of your risk and don't know what you can do to prevent this serious disease. You may be too embarrassed to ask your doctor about changes in your bowel habits or get screened for colorectal cancer. American Cancer Society's Complete... |
 | Mayo Clinic on Digestive Health, Second Edition |
 | Positive Options for Colorectal Cancer: Self-Help and Treatment by Carol Ann Larson Colorectal cancer develops slowly over a period of several years, undetected, usually as polyps. It is a preventable and treatable disease if caught in time, yet most know little about how to read its symptoms. Written for the layperson, this book covers all the uncomfortable questions and answers about the disease, from prevention and warning signs, to screening and diagnosis techniques, to... |
 | What Your Doctor May Not Tell You About(TM) Colorectal Cancer: New Tests, New Treatments, New Hope (What Your Doctor May Not Tell You About...) by Mark Bennett Pochapin The latest edition in the bestselling What Your Doctor May Not Tell You series explodes the myths and misconceptions about the third most common-and second most deadly-form of cancer in the United States. Over 50,000 men and women die from colorectal cancer each year-a particularly alarming statistic since it is also one of the most preventable and treatable cancers. In fact, it is estimated that... |
 | Be a Survivor: Colorectal Cancer Treatment Guide (Be a Survivor) by Vladimir Lange Dr. Lange's comprehensive overview of cancer and treatment options offers detailed information using simple, concise language and a wide variety of color photos and drawings. Colorectal cancer patients need to know more about their disease, yet there is an overload of information. Be a Survivor gives the patient the specific, reliable and necessary information to make good decisions about their... |
 | Modern Management of Cancer of the Rectum Modern Management of Cancer of the Rectum is intended to provide a comprehensive overview of all aspects of rectal neoplasms. It addresses such topics as epidemiology, biology, screening and chemoprevention, the role of imaging in diagnosis, staging and prognosis, radiation therapy, medical and surgical treatment, as well as new modalities of therapy, including laparoscopy, and transanal... |
 | If the Battle is Over, Why am I Still in Uniform? by Brenda Elsagher This story follows a 39-year-old woman through a diagnosis of colorectal cancer and subsequent surgery, with a look at her daily trials in a humorous and honest... |
 | Fluoropyrimidines in Cancer Therapy (Cancer Drug Discovery and Development) Leading cancer researchers update and review the mechanisms of action and the therapeutic selectivity and efficacy of 5-FU with and without leucovorin and its prodrugs in the treatment of colorectal cancer. Among the combination agents considered are UFT/LV, 5-FU/EU, capecitabine (Xeloda), S-1, and a variety of thymidylate synthase inhibitors. The authors discuss the potential advantages and... |
 | Virtual Colonoscopy: A Practical Guide (Medical Radiology) Virtual colonoscopy, or CT colonography, is a novel and rapidly evolving technique for the detection of tumoral lesions in the colon. It promises to be of great value as a screening tool for both colorectal cancer and its adenomatous precursor. With contributions from several leaders in the field, this book addresses all the important issues relating to virtual colonoscopy. There is a particular... |
 | 100 Questions & Answers About Colorectal Cancer by David Bub, Susannah Rose, Douglas Wong This book is a patient-oriented guide to dealing with colorectal cancer. A question and answer format is used to cover many topics related to this... |
| © 2008 BrightSurf.com |